Patent · US Active

L-FABP, natriuretic peptides, and cardiac troponins in subjects in need of cardiac therapy

US8486706B2 · kind B2 · utility

6Cited by

1References

10Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Georg Hess · Mainz, DE
Andrea Horsch · Luzern, CH
Dietmar Zdunek · Tutzing, DE

Key dates

Filing date	Nov 12, 2010
Grant date	Jul 16, 2013
Priority date	—
Expiry date	Nov 12, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10T436/143333
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Disclosed is a method for identifying a subject being susceptible to a cardiac therapy, comprising (a) determining the amounts of liver fatty acid binding protein, and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide in at least one sample of a subject suffering from heart failure, (b) comparing the thus determined amounts to suitable reference amounts, and (c) identifying a subject being susceptible to a cardiac therapy. Also described is a device and a kit adapted to carry out the method of the present invention. Also described is the use of liver fatty acid binding protein and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide for identifying a subject being susceptible to a cardiac therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.